Description
Carcinoembryonic antigen (CEA) is a 180-kDA cell surface glycoprotein overexpressed in 90% of gastrointestinal malignancies, including colon, gastric, rectal, and pancreatic tumors, 70% of lung cancers, and about 50% of breast cancers. Ignyte Bio offers an HLA-A*0201-restricted and CEA-specific CD8 T cell product, generated against the native CEA571-579 (YLSGANLNL) peptide, also known as CEA peptide-1 or CAP-1.